| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5376 | 2010 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4027 | 2013 |
| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ... New England Journal of Medicine 377 (9), 829-838, 2017 | 2285 | 2017 |
| Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2122 | 2014 |
| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1827 | 2014 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1782 | 2014 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1536 | 2012 |
| Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer RC Doebele, AB Pilling, DL Aisner, TG Kutateladze, AT Le, AJ Weickhardt, ... Clinical cancer research 18 (5), 1472-1482, 2012 | 1270 | 2012 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1135 | 2011 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1017 | 2019 |
| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558, 2019 | 1017 | 2019 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1009 | 2016 |
| Acquired resistance to TKIs in solid tumours: learning from lung cancer DR Camidge, W Pao, LV Sequist Nature reviews Clinical oncology 11 (8), 473-481, 2014 | 904 | 2014 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 866 | 2018 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 830 | 2015 |
| Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 818 | 2015 |
| Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ... The Lancet Oncology 19 (12), 1654-1667, 2018 | 741 | 2018 |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ... The lancet oncology 17 (2), 234-242, 2016 | 701 | 2016 |
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer AJ Weickhardt, B Scheier, JM Burke, G Gan, X Lu, PA Bunn Jr, DL Aisner, ... Journal of Thoracic Oncology 7 (12), 1807-1814, 2012 | 689 | 2012 |
| Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ... Journal of Clinical Oncology 33 (17), 1881, 2015 | 681 | 2015 |
